Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in Phase 2b Clinical Trials for Irritable Bowel Syndrome
05.20.2008 Tioga Pharmaceuticals, Inc. today announced that its oral kappa opioid receptor agonist, asimadoline, has demonstrated statistically significant results in treating
Irritable Bowel Syndrome (IBS) patients in a recently completed 596 subject phase 2b randomized, double blind, placebo-controlled, dose ranging, clinical trial.
Asimadoline produced significant improvement in diarrhea-predominant patients across multiple parameters including: pain, urgency, frequency and bloating in both males and females. Effects occurred during the first month of treatment and persisted throughout the three months of treatment.
Benefit was also seen in alternating IBS patients.
Asimadoline appeared to be well tolerated with no Adverse Event occurring in a dose-dependent manner.
...more